Table 3 Analysis of the relationship between neutrophils and lymphocytes before the start of immunotherapy with CPIs.

From: Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients

 

iPD

iSD

iPR

iCR

Neutrophil count

5519 ± 707

5552 ± 909

4415 ± 402

3554 ± 293*

NLR

3.80 ± 0.89

3.12 ± 0.43

3.67 ± 0.50

2.25 ± 0.18

dNLR

2.44 ± 0.47

2.13 ± 0.28

2.34 ± 0.29

1.53 ± 0.09

  1. Neutrophil count (µL); NLR neutrophil-to-lymphocyte ratio (neutrophils/lymphocytes), dNLR derived neutrophil-to-lymphocyte ratio [neutrophils/(leukocytes-neutrophils)]. Best overall response according to iRECIST criteria: iPD, progressive disease (n. 10 patients); iSD, stable disease (n. 13 patients); iPR, partial response (n. 14 patients); complete response, iCR (n. 7 patients). Data are expressed as mean value ± standard error of the mean (SEM). *p = 0.043 iCR versus iPD, assessed by Mann–Whitney U test.
Back to article page